argenx SE (NASDAQ:ARGX) Holdings Lowered by First Trust Advisors LP

First Trust Advisors LP trimmed its stake in shares of argenx SE (NASDAQ:ARGXFree Report) by 3.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,777 shares of the company’s stock after selling 3,246 shares during the period. First Trust Advisors LP owned about 0.13% of argenx worth $30,350,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ARGX. Parkside Financial Bank & Trust purchased a new stake in shares of argenx during the third quarter valued at $28,000. FNY Investment Advisers LLC purchased a new stake in shares of argenx during the fourth quarter valued at $38,000. Benjamin F. Edwards & Company Inc. purchased a new stake in argenx in the 4th quarter worth about $60,000. Principal Securities Inc. purchased a new stake in argenx in the 4th quarter worth about $99,000. Finally, Toronto Dominion Bank lifted its stake in argenx by 174.2% in the 3rd quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock worth $131,000 after acquiring an additional 169 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARGX has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research note on Monday, May 13th. JMP Securities reduced their price objective on argenx from $471.00 to $468.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. Truist Financial increased their price objective on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. HC Wainwright dropped their target price on argenx from $451.00 to $448.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $521.00 target price on shares of argenx in a research report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $520.68.

Get Our Latest Stock Analysis on ARGX

argenx Stock Performance

Shares of NASDAQ ARGX opened at $375.81 on Monday. The firm has a market cap of $22.33 billion, a price-to-earnings ratio of -66.40 and a beta of 0.65. The business’s 50-day simple moving average is $376.30 and its 200-day simple moving average is $392.99. argenx SE has a 52 week low of $327.73 and a 52 week high of $550.76.

argenx (NASDAQ:ARGXGet Free Report) last announced its earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. The business had revenue of $412.51 million for the quarter, compared to the consensus estimate of $404.03 million. During the same quarter in the previous year, the company earned ($0.52) EPS. As a group, equities research analysts forecast that argenx SE will post -2.75 earnings per share for the current year.

argenx Profile

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

See Also

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.